March 3rd 2025
The latest Bench to Bedside column reviews new guidance on the treatment of drug-susceptible and drug-resistance Mycobacterium tuberculosis infections.
February 23rd 2025
WHO: Prepare to Identify Hypervirulent Pathogen
Published: August 5th 2024 | Updated: August 5th 2024The World Health Organization (WHO) warns of a moderate global risk to the presence of the pathogen, hypervirulent Klebsiella pneumoniae (hvKp) sequence type (ST) 23, as it has been reported in at least 1 country in all 6 WHO Regions.
Read More
Effectiveness of Cranberry Supplements in UTI Treatment
Published: August 4th 2024 | Updated: August 4th 2024Given that over 50% of women experience at least one urinary tract infection annually and antimicrobial resistance is on the rise, it's essential to evaluate the evidence for potential non-drug interventions.
Read More
Efficacy of the Antibiotic Omadacycline in Treating Pneumonia
Published: July 22nd 2024 | Updated: July 22nd 2024Paratek Pharmaceuticals has announced results from a Phase 3 study of omadacycline (Nuzyra), demonstrating its non-inferiority to moxifloxacin in treating moderate to severe community-acquired bacterial pneumonia.
Read More
A Pandemic Within a Pandemic: Antimicrobial Resistance During the COVID-19 Pandemic
July 18th 2024A recent report from the CDC highlights how the COVID-19 pandemic has heightened antimicrobial resistance, resulting in a 20% increase in hospital-onset infections caused by key resistant pathogens.
Read More
A Penicillin Allergy Questionnaire for Outpatient Clinics
July 15th 2024Clinicians developed an algorithm and screening questionnaire for outpatient penicillin allergy evaluation, designed to stratify patients into high- and low-risk penicillin allergy groups. Here is the sample questionnaire to consider for use in clinics.
Read More
cUTI Roundtable: Discussing and Diagnosing These Difficult Infections
July 10th 2024This series looks to discuss several topics around these infections including diagnosis, treatment, challenges in managing UTIs in patients with dementia and neurogenic bladders, antibiotic resistance, and considerations for patients and caregiver engagement.
Read More
Jason Roberts, PhD, notes that the BLING study has been a great success for infectious diseases and critical care as a research program, providing strong evidence supporting a meaningful intervention for patients, specifically in clinical cure rates and the occurrence of infections with multiresistant organisms.
Watch
Continuous β-Lactam Infusions Show Promise in the Battle Against Sepsis
June 24th 2024Jason Roberts, PhD, discusses insights from the BLING III trial, outlining its study design and primary outcomes. His analysis centers on the clinical benefits of continuous infusions while addressing the complexities of antibiotic administration in critical care. This is part 1 of a 2-part series.
Watch